סלינקרו 18 מג
lundbeck israel ltd. - nalmefene as hydrochloride dihydrate - טבליות מצופות פילם - nalmefene as hydrochloride dihydrate 18.06 mg - nalmefene
סלינקרו 18 מג
lundbeck israel ltd. - nalmefene as hydrochloride dihydrate - טבליות מצופות פילם - nalmefene as hydrochloride dihydrate 18.06 mg - nalmefene
סובוקסון פילם 4 מג1 מג
naomi shaco-ezra ltd - buprenorphine as hydrochloride; naloxone as hydrochloride dihydrate - buprenorphine as hydrochloride 4 mg; naloxone as hydrochloride dihydrate 1 mg - buprenorphine
סובוקסון פילם 12 מג3 מג
naomi shaco-ezra ltd - buprenorphine as hydrochloride; naloxone as hydrochloride dihydrate - buprenorphine as hydrochloride 12 mg; naloxone as hydrochloride dihydrate 3 mg - buprenorphine
סובוקסון פילם 2 מג0.5 מג
naomi shaco-ezra ltd - buprenorphine as hydrochloride; naloxone as hydrochloride dihydrate - buprenorphine as hydrochloride 2 mg; naloxone as hydrochloride dihydrate 0.5 mg - buprenorphine
סובוקסון פילם 8 מג2 מג
naomi shaco-ezra ltd - buprenorphine as hydrochloride; naloxone as hydrochloride dihydrate - buprenorphine as hydrochloride 8 mg; naloxone as hydrochloride dihydrate 2 mg - buprenorphine
ניקסואיד 1.8 מג
rafa laboratories ltd - naloxone as hydrochloride dihydrate - תמיסה - naloxone as hydrochloride dihydrate 1.8 mg / 0.1 ml - naloxone
טרגין 40
rafa laboratories ltd - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - טבליות בשחרור ממושך - naloxone hydrochloride (as dihydrate) 20 mg; oxycodone hydrochloride 40 mg - naloxone - naloxone - targin is indicated for the relief of moderate to severe pain.the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut
אוויסטה
eli lilly israel ltd, israel - raloxifene hydrochloride - טבליות מצופות פילם - raloxifene hydrochloride 60 mg - raloxifene - raloxifene - evista is indicated for the treatment of osteoporosis in post menopausal women. evista is indicated for the prevention of osteoporosis in post menopausal women . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.
ראלוקסיפן טבע
teva israel ltd - raloxifene hydrochloride - טבליה - raloxifene hydrochloride 60 mg - raloxifene - raloxifene - - treatment of osteoporosis in post menopausal women. - prevention of osteoporosis in post menopausal women .